- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about MRK
Recent news which mentions MRK
Nasdaq Futures Rebound As Traders Eye Apple, Meta, Amazon Earnings: Analyst Flags 'January Barometer' That Bodes Well For The Year
February 01, 2024
From Benzinga
Earnings Scheduled For February 1, 2024
February 01, 2024
From Benzinga
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%
January 30, 2024
From Benzinga
Investor Optimism Around Keytruda Drives Merck Stock To Golden Cross Ahead of Earnings
January 29, 2024
From Benzinga
From Benzinga
Hope for Kidney Cancer Patients, Merck's Keytruda Cuts Risk Of Death By 38% Following Surgery
January 29, 2024
From Benzinga
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
January 29, 2024
From Benzinga
A Bull Market Is Here: 2 Stocks to Buy and Hold for 10 Years
January 28, 2024
From Motley Fool
Merck's Multi-Billion Cancer Drug Keytruda Improves Disease-Free Survival In Advanced Bladder Cancer After Surgery, Data Shows
January 26, 2024
From Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Donald Trump Has Re-Entered The Chat)
January 26, 2024
From Benzinga
From Benzinga
3 S&P 500 Stocks With 127% to 170% Upside in 2024, According to Select Wall Street Analysts
January 25, 2024
From Motley Fool
From Benzinga
From InvestorPlace
From InvestorPlace
This 1 Bullish Move by Merck Could Drive Growth for Years to Come
January 23, 2024
From Motley Fool
7 Exciting Stocks Poised for Explosive Growth in Key Sectors
January 22, 2024
From InvestorPlace
S&P 500 Shatters Records: The Top-Performing Stocks In January 2024
January 19, 2024
From Benzinga
From Benzinga
Why Is Cancer Focused Adagene Stock Plummeting Today?
January 17, 2024
From Benzinga
The 3 Best Dividend Growth Stocks to Buy in January 2024
January 17, 2024
From InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
January 16, 2024
From Benzinga
Merck's Crown Jewel Cancer Drug Keytruda Scores FDA Approval For Third Indication In Cervical Cancer
January 16, 2024
From Benzinga
7 Healthcare Stocks Taking Medicine to the Next Level
January 14, 2024
From InvestorPlace
Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance
January 11, 2024
From Benzinga
The 3 Best Blue-Chip Stocks to Buy in January 2024
January 10, 2024
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.